ArticleIndian dermatology online journal2026
Effectiveness, Safety, and Tolerability of Bilastine Up-Dosing in Chronic Spontaneous Urticaria Uncontrolled with Licensed Doses of Other Second-Generation Antihistamines-An Institution-Based, Open-Label, Single-Group Longitudinal Trial.
Article in Indian dermatology online journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBilastine 20 mg daily is a second-generation antihistamine (sgAH) approved for chronic spontaneous urticaria (CSU). Up-dosing to 40 or 80 mg daily is recommended in uncontrolled patients. AIM AND
objectivesEvaluating the effectiveness, safety, and tolerability of bilastine at 20, 40, and 80 mg daily in CSU patients uncontrolled with licensed doses of other sgAHs. PATIENTS AND
methodsIn this institution-based, open-label, longitudinal trial, CSU patients were evaluated for demography, angioedema, and symptomatic dermographism. Urticaria disease severity was assessed by urticaria activity score (UAS7) score on days 0, 14, 28, and 42. All patients received bilastine 20 mg daily for two weeks. Non-responders (UAS7 > 0) were up-dosed to 40 or 80 mg. Laboratory tests were conducted at baseline and on day 42.
resultsThirty-five CSU patients (mean age 34.5 years, median duration six months) were included. Bilastine 20 mg reduced mean UAS7 score from 25.7 to 6 at day 14 ( P < 0.001), with 16 achieving complete resolution (UAS7 = 0). Among non-responders, up-dosing to 40 mg further reduced UAS7 to 1.9 ( P < 0.001), with 15 more patients achieving UAS7 = 0. Only four required 80 mg, showing minimal additional benefit. ( P = 0.1). Overall, 94% achieved complete control. Somnolence (22%) and headache (50%) occurred at higher doses, but with good tolerability. A higher baseline UAS7 score increased the odds for up-dosing (OR 1.2, P = 0.001). LIMITATIONS: Our study is limited by its small sample size, single-center design, and absence of a control group. Additionally, lack of information on prior antihistamine use or compliance may have confounded the assessment of refractoriness.
conclusionUp-dosing of bilastine is effective, safe, and tolerable in CSU patients uncontrolled with licensed doses of other sgAHs. Almost 90% patients responded to 20-40 mg, while 80 mg did not show a significant additional benefit. A higher baseline UAS7 score may indicate the need for up-dosing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.